Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: Possible significance of CRTC1-MAML2 oncogene

Lung Cancer

Volumn 64, Issue 1, 2009, Pages 129-130

  O'Neill, Iain D ^a  

^a Centre d'Affaires Poincare   (France)

Author keywords

CRTC1 MAML2 oncogene; Gefitinib; Mucoepidermoid carcinoma; t(11 ; 19); Translocation

Indexed keywords

AMPHIREGULIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADENOSQUAMOUS CARCINOMA; ASIAN; CANCER CELL CULTURE; CAUCASIAN; CHROMOSOME 7; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CRTC1 MAML2 ONCOGENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; H 292 CELL; H3118 CELL; HUMAN; LETTER; LUNG CARCINOMA; ONCOGENE; PRIORITY JOURNAL; SALIVARY GLAND;

CARCINOMA, MUCOEPIDERMOID; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 61849115736     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.01.003     Document Type: Letter

References (11)

1. Han S.W., Kim A.P., Jeon Y.K., Oh D.Y., Lee S.H., Kim D.W., et al. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer 61 (2008) 30-34
2. Rossi G., Sartori G., Cavazza A., and Tamberi S. Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. Lung Cancer 63 (2008) 159-160
3. Liu X., and Adams A.L. Mucoepidermoid carcinoma of the bronchus: a review. Arch Pathol Lab Med 131 (2007) 1400-1404
4. Dahse R., and Kosmehl H. Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 99 (2008) 90-92
5. Macarenco R.S., Uphoff T.S., Gilmer H.F., Jenkins R.B., Thibodeau S.N., Lewis J.E., et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21 (2008) 1168-1175
6. O'Neill I.D. t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma. Oral Oncol 45 (2009) 2-9
7. Behboudi A., Enlund F., Winnes M., Andren Y., Nordkvist A., Leivo I., et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 45 (2006) 470-481
8. Tirado Y., Williams M.D., Hanna E.Y., Kaye F.J., Batsakis J.G., and El-Naggar A.K. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer 46 (2007) 708-715
9. Okabe M., Miyabe S., Nagatsuka H., Terada A., Hanai N., Yokoi M., et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res 12 (2006) 3902-3907
10. Coxon A., Rozenblum E., Park Y.S., Joshi N., Tsurutani J., Dennis P.A., et al. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res 65 (2005) 7137-7144
11. Yonesaka K., Zejnullahu K., Lindeman N., Homes A.J., Jackman D.M., Zhao F., et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14 (2008) 6963-6973